[A18-79] Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2019
Commission awarded on 15.11.2018 by the Federal Joint Committee (G-BA).
Airways and respiratory system
Maintenance treatment in adults with moderate to severe COPD who still have symptoms under a combination of a LABA and a LAMA
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-27||Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-79||Commission completed|
|A18-15||Fluticasone furoate/umeclidinium/vilanterol (COPD) – Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2019-05-02 A G-BA decision was published.